01:46 GMT +316 November 2019
Listen Live
    Kirll Dmitriyev, Director General of the Russian Direct Investment Fund

    RDIF Says Launches Alium Pharmaceutical Holding With Chinese, Middle Eastern Partners

    © Sputnik / Evgeni Biyatov
    Business
    Get short URL
    1110
    Subscribe

    MOSCOW (Sputnik) - The consortium led by RDIF holds a 23% stake in Alium, with Sistema and VTB Bank holding 26.3% and 38.5% respectively. The holding has a diversified product portfolio of 200 pharmaceuticals. The production capacity of the merged company is based on the four facilities in Moscow and the Moscow region.

    A consortium of investors, including the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), the Russia-China Investment Fund (RCIF) established by RDIF and China Investment Corporation (CIC), and leading Middle Eastern funds in partnership with Sistema and VTB Bank, have announced the launch of the Alium pharmaceutical holding, according to RDIF.

    The Alium holding is the product of a merger between the pharmaceutical companies Obolenskoe and Binnopharm. Following the merger, Alium is among the top-10 Russian pharmaceutical companies in the sector.

    "The establishment of one of the leading diversified pharmaceutical holdings will enable us to develop the production of high-quality drugs in Russia to improve the quality and life expectancy of the people," Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said.

    According to Dmitriev, the fact that RDIF’s international partners joined the project confirms their interest in investing in Russian medicine and pharmaceuticals, as well as their willingness to work together with RDIF to implement Russian national projects.

    Tags:
    investment, Middle East, China, Russia
    Community standardsDiscussion
    Comment via FacebookComment via Sputnik